Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.

Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers.  Our lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. For more information about the company please visit www.olema.com.

Note: Olema will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview.  Though we use third party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Olema.

Olema Oncology

Welcome to our newest team members, Emma Curran and Liza Bakunina MD, MS! We're excited to have you join Olema, where we're dedicated to transforming the lives of women with cancer. Together, we're #OntoSomethingBigTogether.

Learn more about opportunities at Olema today: https://bit.ly/46oWjdm

Make a meaningful difference for women battling #cancer. Join us on our mission to transform the standard of care for women with cancer. Apply today: https://bit.ly/46oWjdm

#OntoSomethingBigTogether #ClinicalScience #BioTechJobs #CMC #ClinicalSupplyChain #WomensOncology #Oncology #ClinicalDevelopment

And the list goes on! Every day, we find inspiration in the impact of our work and the commitment to scientific advancements.

Make a difference with Olema. Apply today: https://bit.ly/46oWjdm #OntoSomethingBigTogether #Oncology #WomensOncology #Biotech

Today, we honor the legacy of Dr. Martin Luther King Jr., a beacon of hope, justice, and equality. Let us carry his legacy forward, standing united for a better tomorrow. #OntoSomethingBigTogether #MLKDay #MartinLutherKing #Equality

Please welcome our new Senior Medical Director, Elisabeth de Kermadec, MD, MPH! Elisabeth is very excited to join Olema to be able to focus on her professional interest in breast cancer and develop treatments that can improve the lives of patients living with breast cancer.

Elisabeth is a medical gynecologist specializing in #BreastCancer. Elisabeth obtained her medical degree from the Paris V Descartes University in France and her MPH degree from Paris Sud University, France. She did postdoctoral training at the Dana-Farber Cancer Institute in Boston, where she explored fertility issues in young women with breast cancer. #OntoSomethingBigTogether #BreastCancerResearch

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue		9.03K -	11K 21.78%	1.66M 15,018.18%	1.66M 0.30%	377K 77.26%
gross profit		-9.03K -	-11K 21.78%	-1.66M 15,018.18%	-1.66M 0.30%	-377K 77.26%
selling and marketing expenses						-377K -
general and administrative expenses	386K -	403K 4.40%	7.82M 1,841.44%	20.39M 160.62%	24.71M 21.20%	18.82M 23.84%
selling general and administrative expenses	386K -	403K 4.40%	7.82M 1,841.44%	20.39M 160.62%	24.71M 21.20%	18.44M 25.37%
research and development expenses	1.69M -	3.92M 131.54%	13.70M 249.59%	51.10M 272.88%	82.27M 61.01%	86.14M 4.70%
other expenses	-31K -			-47K -	-27K 42.55%
cost and expenses	2.08M -	4.32M 107.94%	21.53M 397.99%	71.49M 232.08%	106.99M 49.65%	104.96M 1.89%
operating expenses	2.08M -	4.32M 107.94%	21.53M 397.99%	71.49M 232.08%	106.99M 49.65%	104.58M 2.25%
interest expense	28K -		653K -		-357K -
ebitda	-2.07M -	-4.31M 108.37%	-21.47M 398.44%	-71.10M 231.17%	-106.99M 50.48%	-104.58M 2.25%
operating income	-2.08M -	-4.32M 107.94%	-21.53M 397.99%	-71.49M 232.08%	-106.99M 49.65%	-104.96M 1.89%
depreciation and amortization	8K -	16K 100%	60K 275%	395K 558.33%	357K 9.62%	377K 5.60%
total other income expenses net	-94K -	7K 107.45%	-593K 8,571.43%	395K 166.61%	2.20M 457.22%	8.31M 277.37%
income before tax	-2.20M -	-4.32M 96.45%	-22.12M 412.53%	-71.10M 221.40%	-104.79M 47.39%	-96.66M 7.76%
income tax expense	-90K -		642K -	-210K 132.71%	-2.20M 948.10%
net income	-2.20M -	-4.32M 96.45%	-22.76M 427.41%	-70.89M 211.41%	-102.59M 44.72%	-96.66M 5.78%
weighted average shs out	14.10M -	40.17M 184.92%	39.31M 2.14%	39.52M 0.55%	40.00M 1.19%	45.25M 13.13%
weighted average shs out dil	14.10M -	40.17M 184.92%	39.31M 2.14%	39.52M 0.55%	40.00M 1.19%	45.25M 13.13%
eps	-0.16 -	-0.11 31.25%	-0.58 427.27%	-1.79 208.62%	-2.56 43.02%	-2.14 16.41%
epsdiluted	-0.16 -	-0.11 31.25%	-0.58 427.27%	-1.79 208.62%	-2.56 43.02%	-2.14 16.41%

COM:OLEMA

Olema Pharmaceuticals Inc (Olema Oncology)

Last Close

11.55

30/08 20:00

Market Cap

649.39M

Beta: -

Volume Today

303.00K

Avg: -

Preview